| Date | Title | Description |
| 19.03.2026 | European stocks close lower as Iran war intensifies; miners lead losses | LONDON — European stocks closed lower on Thursday as the Iran war escalated further and investors navigated the latest interest rate decisions from the region’s central banks.
The pan-European Stoxx 600 ended the session down 2.4%, with all... |
| 12.03.2026 | NOTICE OF ANNUAL GENERAL MEETING IN GETINGE AB (PUBL) | NOTICE OF ANNUAL GENERAL MEETING IN GETINGE AB (PUBL)
Thu, Mar 12, 2026 08:00 CET Report this content
The shareholders of Getinge AB (publ), corporate ID No. 556408-5032, (“Getinge”) are hereby invited to attend the Annual General Meeting (... |
| 26.02.2026 | genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model | LYON, France, Feb. 26, 2026 /PRNewswire/ -- Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in clinical trials. A study in Science Immunology shows ... |
| 01.02.2026 | Llamas are big pharma’s secret weapon to find new drugs | Getting your Trinity Audio player ready...
By Lisa Pham, Bloomberg News
One llama is sprawled on the grass with its neck craned, basking in a patch of sunshine. Another stands on a dirt hill, ears flattened defiantly. A third rushes to gree... |
| 15.01.2026 | ‘Innovation Germany’ zeigt das Engagement von argenx für die Versorgung von Patient:innen mit Autoimmunerkrankungen. | MUNICH, GERMANY, January 15, 2026 /EINPresswire.com/ -- Eines der führenden Biotech-Unternehmen Europas treibt durch Zusammenarbeit und Partnerschaften Präzisionstherapien für Autoimmunerkrankungen mit hohem ungedecktem Bedarf voran
argenx ... |
| 20.12.2025 | US Drug Prices Face Seismic Shift: Pharma Giants Negotiate Deep Cuts | The American healthcare landscape is transforming. US drug prices, long the world's highest, face unprecedented pressure. President Trump drove an aggressive campaign to lower prescription costs. His administration pushed the Most Favored N... |
| 19.12.2025 | This is how exposed European Big Pharma is to the U.S. | The U.S. is the biggest single market for most pharma and biotech firms.
Among the 10 largest biopharmaceutical companies in the Stoxx 600 health index, five get a majority of their total sales from the U.S.
AstraZeneca gets 42% of sales fr... |
| 18.12.2025 | Camilla Sylvest is proposed for Getinge AB’s Board of Directors | Camilla Sylvest is proposed for Getinge AB’s Board of Directors
Thu, Dec 18, 2025 09:00 CET Report this content
The Nomination Committee of Getinge AB (publ) has decided to propose to the Annual General Meeting 2026 that the Meeting elects ... |
| 15.12.2025 | European markets close higher but defense, pharma stocks falter | LONDON — European stocks ended the session in positive territory at the start of a busy week for Europe's central banks.
The pan-European Stoxx 600 provisionally ended the session up 0.8%, with most sectors and major bourses in the green.
I... |
| 28.11.2025 | American Neurology Summit 2025 Achieves Major Success With Full Attendance and High Engagement | ANS2025 served as a national platform for neurologists, primary care clinicians, nurses, and researchers to engage in high-impact education on the latest advancements in neurological care. The hybrid CME/CE event featured expert sessions on... |
| 24.11.2024 | OncoVerity and Steritas: Pioneering New Frontiers in Cancer and Autoimmune Treatment | In the world of medicine, innovation is the lifeblood that fuels progress. Two companies, OncoVerity and Steritas, are at the forefront of this revolution, each tackling significant health challenges with groundbreaking approaches. OncoVeri... |
| 22.11.2024 | OncoVerity Raises Extended Series A | OncoVerity, an Aurora, CO-based company which specializes in applying advanced bioinformatics to drug development, raised a Series A extension funding.
The amount of the deal was not disclosed.
The round was led by existing investors argenx... |
| 20.11.2024 | Steritas announces collaboration with argenx to advance evidence for novel steroid-sparing therapeutics | First-in-class steroid-toxicity outcome assessments licensed by argenx to support development of novel steroid-sparing therapeutics for autoimmune diseases
Boston, MA, USA, 19 November 2024: Steritas LLC., a company dedicated to enhancing c... |
| 06.05.2024 | Komodo Health & Partners Present 33 Real-World Evidence Research Studies at ISPOR 2024 | Researchers Used Komodo’s Healthcare Map to Uncover Insights Across Oncology, Women’s Health, Mental Health, Neurology, and more
Komodo Insights Power Three Studies Named Finalists for ISPOR 2024 Research Presentation Awards
SAN FRANCISCO &... |
| 07.03.2024 | argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting | - |
| 17.04.2023 | argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology | Genmab and argenx have entered into a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies
Discovery programs against two differentiated targets are underway
argenx SE and ... |
| 16.01.2023 | argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director | January 16, 2023
Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary gener... |
| 06.06.2022 | Medison Pharma Announces Multi-Regional Partnership Agreement with argenx to Commercialize Efgartigimod Across Europe and Israel | PETACH TIKVAH, Israel, June 6, 2022 /PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today an exclusive ... |
| 05.05.2022 | Argenx Stock Climbs as Sales of New Drug Blow Past Expectations | Sales of argenx new, potential blockbuster Vyvgart are off to a very strong start, coming in many times higher than analysts expected for the drug’s first quarter on the market.
Argenx (ticker: ARGX) reported $21.2 million in quarterly sale... |
| 19.12.2021 | FDA approval of Argenx neuromuscular disease therapy is first in new drug class | An Argenx drug developed to treat the rare neuromuscular disorder generalized myasthenia gravis is now approved by the FDA, the first therapy in a new class of medicines that takes a novel approach to treating autoimmune conditions.
Myasthe... |
| 17.06.2021 | ARGENX SE
Argenx's drug effective against muscle-weakening disease myasthenia gravis | June 16 (Reuters) - An experimental drug developed by argenx SE led to improvements in daily activities, including chewing and swallowing, in patients suffering from a muscle-weakening autoimmune disease, according to data published in the ... |
| 28.05.2021 | BB Biotech : investment trust review highlights long t... | Launched in 1993, BB Biotech (BION) is one of the largest specialist funds investing in the fast-growing sector of
biotechnology. It is managed by Bellevue Asset Management, a healthcare investment manager headquartered in Switzerland, and ... |
| 26.05.2020 | Pivotal myasthenia gravis data from argenx augur well for FcRn inhibitors in development | Leading the pack of biotechs vying for a piece of the generalized myasthenia gravis (gMG) market with an FcRn inhibitor, argenx on Tuesday unveiled keenly anticipated positive late-stage data on its lead asset, bringin... |
| 12.03.2020 | Precision biologics: the key to reducing antibiotic use in livestock? | Pathogens, as is clear to anyone tracking the outbreak of Covid-19 on humans or African Swine Fever on pigs, can inflict disastrously global impacts on public health, as well as wreaking havoc on vital food supply chains. To date, preventin... |
| 03.12.2018 | J&J pays $500M in cash to grab rights to a new star cancer drug at argenx | J&J execs believe they have found their next big cancer drug.
Early Monday the pharma giant announced that it was paying Belgium’s argenx $500 million — $300 million as an upfront and $200 million for equity — to grab t... |
| - | FDA approval of Argenx neuromuscular disease therapy is first in new drug class | An Argenx drug developed to treat the rare neuromuscular disorder generalized myasthenia gravis is now approved by the FDA, the first therapy in a new class of medicines that takes a novel approach to treating autoimmune conditions.
Myasthe... |
| - | Europe stocks close lower as momentum wanes after China data; Argenx up 31% | This is CNBC’s live blog covering European markets. |
